Summary In this episode of The Defenders Log, Paul Mockapetris, the architect of DNS, discusses the evolving role of the Domain Name System from a simple directory to a sophisticated security tool. He ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for the next decade.

Nostalgia has become one of the most powerful currencies in Bollywood’s contemporary marketing apparatus. The recycling of ...

This article, presented in the backdrop of the debates on the state of political theory in India, argues that the terms of debate need to shift to include the question of method of doing political ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Tessellations aren’t just eye-catching patterns—they can be used to crack complex mathematical problems. By repeatedly reflecting shapes to tile a surface, researchers uncovered a method that links ...

Threat actors are exploiting complex routing scenarios and misconfigured spoof protections to send spoofed phishing emails, ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...